We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 337

Health Plans and Pharmacy Benefit Managers - Past and Future
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 13 2018

Historically, health plans and pharmacy benefit managers (“PBMs”) have been uncomfortable neighbors. Plans provide drug coverage, but contract out the

OIG Reports on Impact of “High-Priced Drugs” on Medicare Part D Catastrophic Coverage Spending
  • Reed Smith LLP
  • USA
  • January 30 2017

At the request of Congress and others, the Office of Inspector General (OIG) conducted a review of “high-priced drugs” (defined by OIG as exceeding

Pfizer, Flynn Pharma fined for abusing dominant market positions
  • Brodies LLP
  • United Kingdom
  • December 12 2016

The Competition and Markets Authority (“CMA”) has fined pharmaceutical manufacturer Pfizer and pharmaceutical distributor Flynn Pharma a combined

The Health Policy Commission’s Annual Cost Trends Hearings
  • Mintz
  • USA
  • November 1 2016

The Massachusetts Health Policy Commission conducted its fourth annual Cost Trends Hearing on October 17 and 18, 2016, under the requirements of

Importing Pharmaceuticals to the Turkish Market
  • Moroğlu Arseven
  • Turkey
  • October 5 2016

Given the potential risks posed to public health, the pharmaceutical sector is one of the most strictly regulated sectors in many countries

Romanian tax authorities go public on the first VAT fixed establishment assessment in the pharmaceutical industry
  • DLA Piper
  • Romania
  • August 24 2016

The Romanian tax authorities just issued a press release regarding an audit performed on the activity carried out by the local subsidiary of a

Italian Competition Authority Opens Sector Inquiry on Vaccines Competition
  • Jones Day
  • European Union, Italy
  • July 18 2016

Over the last few years the pharmaceutical industry in Italy has attracted increasingly intensive antitrust scrutiny. Last month the Italian

Commission consults on EU transparency rules in relation to pricing and reimbursement of medicines
  • Matheson
  • European Union, Ireland
  • May 2 2011

European Member States are responsible for their own health insurance schemes and for determining the pricing for medicines and their reimbursement status.

Premarket notification (510k), Pt. i: ownership and licensing
  • Hodgson Russ LLP
  • USA
  • March 21 2011

We are often asked by our clients about the transfer of the FDA marketing approvals from one entity to another.

India ponders domestic impact of biopharma takeovers
  • Shook Hardy & Bacon LLP
  • India
  • March 10 2011

According to a news source, recent takeovers of India's key drug companies by foreign pharmaceutical interests have policymakers worried about the potential impact on domestic drug markets and prices.